Skip to content


Braftovi (encorafenib) is a small molecule pharmaceutical. Encorafenib was first approved as Braftovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms and melanoma. Braftovi's patents are valid until 2033-08-05 (FDA).
Trade Name Braftovi
Common Name Encorafenib
Indication colorectal neoplasms, melanoma
Drug Class Raf kinase inhibitors
Get full access now